Table 1. Clinical and Pathological Features of Lung Adenocarcinoma Cancer Patients.
| Variable | TMCohort | HMCohort | MGHCohort | DukeCohort | ACCCohort | |
| (Exploration cohort) | (Validation cohort 1) | (Validation cohort 2) | (Validation cohort 3) | (Validation cohort 4) | ||
| Number of patients | 186 | 256 | 125 | 58 | 117 | |
| Men | 83 (44.6%) | 140 (54.7%) | 53 (42.4%) | 27 (46.6%) | 60 (51.3%) | |
| Women | 103 (55.4%) | 116 (45.3%) | 72 (57.6%) | 31 (53.4%) | 57 (48.7%) | |
| Age (years) | Median | 64 | 66 | 64 | 67 | 61 |
| Range | 35–82 | 33–87 | 33–88 | 43–83 | 31–84 | |
| Disease stage | I | 119 (64.0%) | 158 (61.7%) | 76 (60.8%) | 34 (58.6%) | 79 (67.5%) |
| II | 46 (24.7%) | 49 (19.2%) | 24 (19.2%) | 7 (12.1%) | 13 (11.1%) | |
| III | 21 (11.3%) | 47 (18.4%) | 10 (8.0%) | 14 (24.1%) | 25 (21.4%) | |
| IV | 0 (0%) | 0 (0%) | 15 (12.0%) | 3 (5.2%) | 0 (0%) | |
| NA | 2 (0.7%) | |||||
| Adjuvant chemotherapy | ||||||
| Yes | 56 (30.1%) | 33 (12.9%) | 0 | 0 | 0 | |
| No | 96 (51.6%) | 137 (53.5%) | 0 | 0 | 117 (100%) | |
| NA | 34 (18.3%) | 86 (33.6%) | 125 (100%) | 58 (100%) | 0 | |
| Number of deaths | 74 | 162 | 71 | 32 | 49 |
Abbreviations: TM, Toronto and Memorial Sloan-Kettering Cancer Center; HM, H. Lee Moffit Cancer Center and University of Michigan; MGH, Massachusetts General Hospital; ACC, Aichi Cancer Center; NA, Not available.